uniQure Shares Crater as Four-Year Clinical Data Undermines BLA

The discrepancy between the two data sets has triggered a formal investigation by the firm SueWallSt into potential securities law violations. While the company reported a 75% slowing of disease progression at the 36-month mark, the 48-month analysis indicated that benefit had slipped to 44% under the composite Uniform Huntington’s Disease Rating Scale. This decline arrived just weeks after uniQure submitted a Biologics License Application to the FDA, a filing based exclusively on the more favorable three-year data.

The investigation, led by attorney Joseph E. Levi, focuses on whether the company issued materially misleading statements regarding the durability of AMT-130’s clinical performance. Legal representatives for the firm are currently reviewing investor losses, noting that eligibility for potential recovery extends to shareholders who purchased stock at prices allegedly inflated by the company's previous disclosures, regardless of whether they have since sold their positions.